oncolytic adenovirus therapy/PD-1 checkpoint inhibitor (Shanghai Yuansong Biotechnology)

N/A

Report date: 2025/01/26 16:39:07

Base Information

Drug Nameoncolytic adenovirus therapy/PD-1 checkpoint inhibitor (Shanghai Yuansong Biotechnology)
Drug Alias NamePD-1 checkpoint inhibitor (Shanghai Yuansong Biotechnology)oncolytic adenovirus therapy expressing fully human anti-PD-1 ScFv-Fc (Shanghai Yuansong Biotechnology)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Oncolytic virus
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Yuansong Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Yuansong Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A